Pharmacogenetic Information in Clinical Guidelines: The European PerspectiveSwen, J. J., Nijenhuis, M., van Rhenen, M., de Boer-Veger, N. J., Buunk, A-M., Houwink, E. J. F., Mulder, H., Rongen, G. A., van Schaik, R. H. N., van der Weide, J., Wilffert, B., Deneer, V. H. M., Guchelaar, H-J. & Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP), May-2018, In : Clinical Pharmacology & Therapeutics. 103, 5, p. 795-801 7 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).(1-3) In addition, patients are willing to consent to participate in PGx implementation studies.(4) However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test.(1,2) Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients.(5,6)
|Number of pages||7|
|Journal||Clinical Pharmacology & Therapeutics|
|Early online date||20-Feb-2018|
|Publication status||Published - May-2018|
- DECISION-SUPPORT, PREEMPTIVE PHARMACOGENOMICS, NATIONWIDE SURVEY, IMPLEMENTATION, MEDICINE, NETWORK, CYP2D6, MODEL, POLYPHARMACY, CONSORTIUM